扶正解毒抗癌方治疗晚期非小细胞肺癌的临床效果  

Efficacy of Fuzheng Jiedu Kang’ai Prescription in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：吕星旺 杜兴龙[1] LYU Xingwang;DU Xinglong(Dept.of Oncology,Chuzhou the First People’s Hospital,Anhui Chuzhou 239000,China)

机构地区：[1]滁州市第一人民医院肿瘤一科,安徽滁州239000

出　　处：《中国医院用药评价与分析》2020年第3期283-285,289,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：安徽省科技计划项目(No.15011d0405)。

摘　　要：目的:探讨扶正解毒抗癌方对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及对患者化疗后骨髓抑制的影响。方法:选取2016年1月至2019年3月滁州市第一人民医院收治的NSCLC患者100例,按照随机数字表法分为对照组和研究组,每组50例。对照组患者采用常规化疗,研究组患者在对照组的基础上加用扶正解毒抗癌方,两组患者连续治疗2个化疗周期。观察两组患者的临床疗效,分别于治疗前后测定白细胞计数、血小板计数及血红蛋白水平,比较两组患者治疗后骨髓抑制发生情况和卡氏(Karnofsky,KPS)评分的差异。结果:研究组患者的总有效率为62.00%(31/50),明显高于对照组的36.00%(18/50),差异有统计学意义(P<0.05)。治疗后,两组患者白细胞计数、血小板计数及血红蛋白水平均明显低于治疗前,但研究组患者上述指标水平明显高于对照组,差异均有统计学意义(P<0.05)。研究组患者骨髓抑制发生率为38.00%(19/50),明显低于对照组的68.00%(34/50),差异有统计学意义(P<0.05)。治疗后,研究组患者KPS评分提高率和稳定率分别为34.00%(17/50)、46.00%(23/50),明显优于对照组的14.00%(7/50)、16.00%(8/50),差异均有统计学意义(P<0.05)。结论:扶正解毒抗癌方联合常规化疗治疗晚期NSCLC的疗效显著,能够减轻患者化疗后骨髓抑制情况,提高患者生活质量。OBJECTIVE:To probe into the efficacy of Fuzheng Jiedu Kang’ai prescription in the treatment of advanced non-small cell lung cancer(NSCLC)and its effects on bone marrow suppression after chemotherapy.METHODS:Totally 100 patients with NSCLC admitted into Chuzhou the First People’s Hospital from Jan.2016 to Mar.2019 were extracted to be divided into the control group and the study group via the random number table,with 50 cases in each group.The control group was treated with conventional chemotherapy,while the study group received Fuzheng Jiedu Kang’ai prescription on the basis of the control group.Two groups were treated continuously for 2 cycles of chemotherapy.The clinical efficacy,white blood cell count,platelet count and hemoglobin count before and after treatment were recorded,differences of incidence of bone marrow suppression and Karnofsky(KPS)score of two groups were compared.RESULTS:The total effective rate of the study group was 62.00%(31/50),significantly higher than 36.00%(18/50)of the control group,the difference was statistically significant(P<0.05).After treatment,the white blood cell count,platelet count and hemoglobin count of two groups were significantly lower than those before treatment,yet the study group was significantly higher than the control group,with statistically significant differences(P<0.05).The incidence of bone marrow suppression in the study group was 38.00%(19/50),significantly lower than 68.00%(34/50)in the control group,and the difference was statistically significant(P<0.05).After treatment,the improvement rate and stability rate of KPS score in the study group[34.00%(17/50)and 46.00%(23/50)]were significantly better than those in the control group[14.00%(7/50)and 16.00%(8/50)],with statistically significant differences(P<0.05).CONCLUSIONS:The efficacy of Fuzheng Jiedu Kang’ai prescription in the treatment of NSCLC is significant,which can reduce bone marrow suppression in patients after chemotherapy and improve patients’quality of life.

关 键 词：晚期非小细胞肺癌 扶正解毒抗癌方 化疗 骨髓抑制 

分 类 号：R932[医药卫生—生药学]